AI assistant
BOIRON Earnings Release 2023
1161_iss_2023-04-28_e4209ff8-2c8c-4832-914b-6778d3b4a463.pdf
Earnings Release
Open in viewerOpens in your device viewer
BOTRON®
April 27, 2023
2023 FIRST QUARTER BOIRON SALES
(Unaudited data)
| In thousands of euros | 2023 | 2027 | Variation at | Variation at |
|---|---|---|---|---|
| current | constant | |||
| exchange rates | exchange rates | |||
| France | 54,580 | 77,055 | -29.2% | -29.2% |
| Europe (excluding France) | 39,220 | 34,476 | +13.8% | +9.0% |
| North America | 33,279 | 28,944 | +15.0% | +11.0% |
| Other countries | 5,220 | 5,305 | -1.6% | -3.9% |
| Group total | 132,299 | 145,780 | -9.2% | -11.2% |
| Variation at | Variation at | |||
| In thousands of euros | 2023 | 2022 | current | constant |
| exchange rates | exchange rates | |||
| Non-proprietary homeopathic medicines | 45,234 | 45,516 | -0.6% | -1.4% |
| Homeopathic specialties | 80,055 | 67,100 | +19.3% | +15.6% |
| Other health products | 7,010 | 33,164 | -78.9% | -79.0% |
| Group total | 132,299 | 145,780 | -9.2% | -11.2% |
Change in sales
Sales for the first quarter of 2023 were down 9.2%, heavily impacted by a challenging basis for comparison due to strong COVID test sales in the first quarter of 2022. This decline in COVID test sales was primarily localized in France.
Excluding these tests, sales were up 10.6%.
Changes in non-proprietary homeopathic medicine sales were varied. They continued to decline in France while increasing in almost all other countries, particularly the United States.
Homeopathic specialty sales continued to grow in most countries, across all products. This performance is even more remarkable given that sales had already increased significantly in 2022.
Two new homeopathic medicines were launched in France during the first quarter: Prélinium®, traditionally used in the long-term treatment of seasonal allergic rhinitis, and Idryline®, eye drops developed for the symptoms of dry eye.
Outlook
In 2023, Group sales may be impacted by the decrease in COVID test sales, by pressure on the supply of raw materials and by the geopolitical situation in certain parts of the world. Nevertheless, upcoming launches and current momentum in homeopathic specialties enable us to maintain our target of increasing sales.
We continue to put all our energy and determination into ensuring that every patient in the world can take advantage of homeopathy and our other healthcare solutions, thereby supporting a more humane, efficient and sustainable healthcare system.
Laboratoires BOIRON
Our next updates:
- The Mixed Shareholders' Meeting will be held on Mat BOIRON headquarters, 2 wenve de l'Ouest Lyonnais, 69510 MESSMY FRANCE.
- June 2, 2023: ofter approval by the Mixed Shareholders' Meeting, payment of the proposed dividend (€1.10 per share).
- July 18, 2023: after the close of the stock market, publication of the sales on June 30, 2023.
- Person responsible for financial information: Valérie Lorentz-Poinsot
Contact for financial information: Fabrice Rey
ISIN Code: FR0000061129 (BOI) - Bloomberg: BOI FP - Reuters: BOIR.PA
lnvestor relations: +33 (0) 4.37.41.84.01 - e-mail: [email protected]
The group's financial information is online at : www.boironfinance.com